Background Mitochondrial dysfunction plays a pivotal role in the progression of left ventricular （LV） remodeling and heart failure （HF）. Recombinant human neuregulin-1 （rhNRG-1） improves cardiac function in mode...Background Mitochondrial dysfunction plays a pivotal role in the progression of left ventricular （LV） remodeling and heart failure （HF）. Recombinant human neuregulin-1 （rhNRG-1） improves cardiac function in models of experimental HF and in clinical trials; however, its impact on mitochondrial function during chronic HF remains largely unknown. The purpose of this study was to investigate whether rhNRG-1 could attenuate the functional and structural changes that occur in cardiac mitochondria in a rat model of HF induced by myocardial infarction.展开更多
Hypereosinophilic syndrome （HES） is a rare disorder that can be seen in various organ systems, but its major tissue target is the heart.＇ The most characteristic cardiovascular abnormality in HES is endomyocardial ...Hypereosinophilic syndrome （HES） is a rare disorder that can be seen in various organ systems, but its major tissue target is the heart.＇ The most characteristic cardiovascular abnormality in HES is endomyocardial fibrosis, initially described in 1936 by Loffler, who called it ＂fibroplastic parietal endocarditis with blood eosinophilia.＂ The overall prognosis of patients with Loffler endocarditis is very poor. Current treatments include anticoagulation and anti-eosinophils therapy, and surgery only has been used in selected cases.展开更多
文摘Background Mitochondrial dysfunction plays a pivotal role in the progression of left ventricular （LV） remodeling and heart failure （HF）. Recombinant human neuregulin-1 （rhNRG-1） improves cardiac function in models of experimental HF and in clinical trials; however, its impact on mitochondrial function during chronic HF remains largely unknown. The purpose of this study was to investigate whether rhNRG-1 could attenuate the functional and structural changes that occur in cardiac mitochondria in a rat model of HF induced by myocardial infarction.
文摘Hypereosinophilic syndrome （HES） is a rare disorder that can be seen in various organ systems, but its major tissue target is the heart.＇ The most characteristic cardiovascular abnormality in HES is endomyocardial fibrosis, initially described in 1936 by Loffler, who called it ＂fibroplastic parietal endocarditis with blood eosinophilia.＂ The overall prognosis of patients with Loffler endocarditis is very poor. Current treatments include anticoagulation and anti-eosinophils therapy, and surgery only has been used in selected cases.
